lifestyle.folsomlocalnews.com/

Author: Neomorph, Inc.

Neomorph Appoints Biopharma Leader Robert J. Hugin as Chairman of the Board

May 13, 2026
Neomorph to Highlight Progress in Targeted Protein Degradation Science at the American Association for Cancer Research Annual Meeting

April 14, 2026
Neomorph Announces Closing of $100 Million Series B Financing

April 13, 2026
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

February 3, 2026